SARS-CoV-2(7) COVID-19(6) coronavirus(4) attenuate(3) acute respiratory syndrome(3) Drug repurposing(3) younger patients(3) clinical trial(3) downstream(3) Human(3) Health(3) susceptible(3) COVID-19 hospitalization(3) blunting(3) affected(3) muscle protein synthesis.(3) demonstrated(3) causative agent(3) acute respiratory syndrome coronavirus 2(3) Severe infection(3) effectors(3) Hospitalization(3) Effect(3) Rapamycin(3) death(3) Cell(3) greater(3) anabolic resistance(3) the disease(3) MPS(3)